NCT02733250 (URCOH-PMS-001) is a Phase 1, PHASE2 clinical trial of Pembrolizumab in Lung Cancer, sponsored by Centre hospitalier de l'Université de Montréal (CHUM).

Who is sponsoring NCT02733250?

NCT02733250 is sponsored by Centre hospitalier de l'Université de Montréal (CHUM).

What drugs are being tested in NCT02733250?

Interventions in NCT02733250: Pembrolizumab, Nab-Paclitaxel.

What condition does NCT02733250 study?

NCT02733250 studies Lung Cancer.

Is NCT02733250 still recruiting?

NCT02733250 is currently completed. Last updated 16 February 2021.

Last reviewed 2021-02-16 · How we verify

NCT02733250: URCOH-PMS-001

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer

Completed Phase 1, PHASE2 Last updated 16 February 2021

What this trial tests

Phase 1, PHASE2 trial testing Pembrolizumab in Lung Cancer in 10 participants. Completed in 13 December 2019.

Timeline

13 March 2017

Primary endpoint
13 April 2019

13 December 2019

Quick facts

Lead sponsor	Centre hospitalier de l'Université de Montréal (CHUM)
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	13 March 2017
Primary completion	13 April 2019
Estimated completion	13 December 2019
Sites	2 locations across Canada

Drugs / interventions tested

Pembrolizumab (pembrolizumab) — full drug profile →
Nab-Paclitaxel (nab-paclitaxel) — full drug profile →

Conditions studied

Lung Cancer — all drugs for Lung Cancer →

Sponsor

Centre hospitalier de l'Université de Montréal (CHUM)

Who can join

18 and older, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the optimal dose of nab-paclitaxel to be safely administered in combination with pembrolizumab in patients with advanced inoperable non-small cell lung cancer. The study is also aimed at evaluating the efficacy of the combination therapy.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.
Wu M, Huang Q, Xie Y, Wu X, et al · · 2022 · cited 336× · PMID 35279217 · DOI 10.1186/s13045-022-01242-2
<i>nab</i>-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors.
Soliman HH. · · 2017 · cited 65× · PMID 28053544 · DOI 10.2147/ott.s122974
Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non-Small Cell Lung Cancer.
Li JX, Huang JM, Jiang ZB, Li RZ, et al · · 2019 · cited 45× · PMID 31838881 · DOI 10.1177/1534735419890020
Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials.
Johnson CB, Win SY. · · 2018 · cited 26× · PMID 29632719 · DOI 10.1080/2162402x.2017.1408744
New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab.
Bylicki O, Paleiron N, Rousseau-Bussac G, Chouaïd C. · · 2018 · cited 12× · PMID 30038505 · DOI 10.2147/ott.s154606

Verify or expand the search:

Other trials of Pembrolizumab

Trials testing the same drug.

NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
NCT07275216 — Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Stand · Phase 2 · not yet recruiting
NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT06724042 — Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors · Phase 1 · not yet recruiting
NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other Centre hospitalier de l'Université de Montréal (CHUM) trials

Trials by the same sponsor.

NCT06735638 — Outside the Cage (OTC) Robotic Esophagectomy · Phase 1 · not yet recruiting
NCT05225272 — Effectiveness of an Enhanced Recovery After Surgery Protocol in Patients Undergoing On-pump Cardiac Surgery · not yet recruiting
NCT07533253 — Rescue Distal Thrombectomy in Treatment for Persistent Distal Occlusions · NA · not yet recruiting
NCT07497061 — Comparison of Two Surgical Techniques for the Treatment of Trigger Fingers: Longitudinal Opening Versus Complete A1 Pull · NA · not yet recruiting
NCT07196410 — KAN-004 for Immune-Related Diarrhea or Colitis · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02733250 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre hospitalier de l'Université de Montréal (CHUM)
Last refreshed: 16 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02733250.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing